{"id":195,"date":"2024-11-13T22:00:00","date_gmt":"2024-11-13T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=195"},"modified":"2025-09-04T14:15:03","modified_gmt":"2025-09-04T14:15:03","slug":"china-bd-2024-sunshine-lake-hec-and-apollo-enters-a-938-million-usd-license-on-fgf21-glp-1-bi-specific-fusion-protein-hec88473-apl-18881","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/195.html","title":{"rendered":"[China BD 2024] Sunshine Lake (HEC) and Apollo\u00a0 enters a 938 million USD License on FGF21\/GLP-1 Bi-specific\u00a0Fusion Protein HEC88473 (APL-18881)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2024-11-12 (November 12, 2024)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: HEC88473 (APL-18881)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor:  Sunshine Lake Pharma (member of HEC Group, China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Apollo Therapeutics\uff08UK)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Bi-specific fusion protein (BsFP\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: long-acting GLP-1\/FGF21 dual agonist<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase II, China<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sunshine Lake has granted Apollo development, manufacturing and commercialization rights of APL-18881 (HEC88473) outside of China for all current and future therapeutic indications.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sunshine Lake will retain development, manufacturing and commercialization rights  in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sunshine Lake is to receive\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of\u00a0$12 million;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory and commercial milestone payments of up to $926 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tiered royalties ranging from high single to low double digits on net sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.apollotx.com\/news\/apollo-therapeutics-signs-exclusive-ex-china-license-from-sunshine-lake-pharma-for-clinical-stage-fgf21-glp-1-dual-receptor-agonist\/\">Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 \/ GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications | Apollo Therapeutics (apollotx.com)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-11-12 (November 12, 2024) Asset Name: HEC88473 (APL-18881) Licensor: Sunshine Lake Pharma (member of &hellip; <a title=\"[China BD 2024] Sunshine Lake (HEC) and Apollo\u00a0 enters a 938 million USD License on FGF21\/GLP-1 Bi-specific\u00a0Fusion Protein HEC88473 (APL-18881)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/195.html\"><span class=\"screen-reader-text\">[China BD 2024] Sunshine Lake (HEC) and Apollo\u00a0 enters a 938 million USD License on FGF21\/GLP-1 Bi-specific\u00a0Fusion Protein HEC88473 (APL-18881)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-195","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=195"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/195\/revisions"}],"predecessor-version":[{"id":196,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/195\/revisions\/196"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}